2024

Yu, Y.-L. et al. (2024) Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart, 110(19), pp. 1180-1187. (doi: 10.1136/heartjnl-2023-323796) (PMID:38729636)

Aguiar-Neves, I. et al. (2024) Health status and effects of spironolactone in people at high risk of heart failure: the Heart OMics in AGEing (HOMAGE) randomised trial. Clinical Cardiology, (Accepted for Publication)

Kobayashi, M. et al. (2024) Proteomic profiles of left atrial volume and its influence on response to spironolactone: findings from the HOMAGE trial and STANISLAS cohort. European Journal of Heart Failure, 26(5), pp. 1231-1241. (doi: 10.1002/ejhf.3202) (PMID:38528728)

Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, 30(4), pp. 618-623. (doi: 10.1016/j.cardfail.2023.11.020) (PMID:38122924)

Sattar, N. et al. (2024) Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: principal findings and meta-analysis with the DELIVER trial. European Journal of Heart Failure, 26(4), pp. 900-909. (doi: 10.1002/ejhf.3221) (PMID:38558521)

Santos-Ferreira, D. et al. (2024) Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial. ESC Heart Failure, 11(1), pp. 209-218. (doi: 10.1002/ehf2.14465) (PMID:37939716) (PMCID:PMC10804163)

2023

Neves, J. S. et al. (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp. 517-525. (doi: 10.1016/j.jacc.2023.05.048) (PMID:37532422)

Kobayashi, M. et al. (2023) A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial. European Journal of Heart Failure, 25(8), pp. 1284-1289. (doi: 10.1002/ejhf.2859) (PMID:37062878)

Monzo, L., Girerd, N., Duarte, K., Ferreira, J. P., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Pocock, S. J., Pitt, B. and Zannad, F. (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial. European Journal of Heart Failure, 25(8), pp. 1444-1449. (doi: 10.1002/ejhf.2952) (PMID:37370197)

Verma, S. et al. (2023) Presence of peripheral artery disease is associated with increased risk of heart failure events: insights from EMPEROR-Pooled. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(7), pp. 1334-1337. (doi: 10.1161/ATVBAHA.123.319156) (PMID:37199158) (PMCID:PMC10281175)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Girerd, N. et al. (2023) Protein biomarkers of new-onset heart failure: insights from the Heart Omics and Ageing cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circulation: Heart Failure, 16(5), pp. 426-441. (doi: 10.1161/CIRCHEARTFAILURE.122.009694) (PMID:37192292) (PMCID:PMC10179982)

Ferreira, J. P. et al. (2023) Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: pooled analysis of three randomized trials. International Journal of Cardiology, 377, pp. 86-88. (doi: 10.1016/j.ijcard.2023.01.088) (PMID:36738846)

Ferreira, J. P. et al. (2023) Effect of spironolactone on QRS duration in patients at risk for heart failure (from the HOMAGE trial). American Journal of Cardiology, 191, pp. 39-42. (doi: 10.1016/j.amjcard.2022.12.016)

Anker, S. D. et al. (2023) Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. European Journal of Heart Failure, 25(1), pp. 117-127. (doi: 10.1002/ejhf.2728) (PMID:36325584)

Ferreira, J. P. et al. (2023) Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. European Journal of Heart Failure, 25(1), pp. 108-113. (doi: 10.1002/ejhf.2726) (PMID:36303266)

2022

Zannad, F. et al. (2022) Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights from the EMPEROR program. European Heart Journal, 43(48), pp. 4991-5002. (doi: 10.1093/eurheartj/ehac495) (PMID:36017745)

Ferreira, J. P., Pitt, B., McMurray, J. J.V. , Pocock, S. J., Solomon, S. D., Pfeffer, M. A., Zannad, F. and Rossignol, P. (2022) Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs. JACC: Heart Failure, 10(11), pp. 842-850. (doi: 10.1016/j.jchf.2022.06.010) (PMID:36328653)

Bedrouni, W. et al. (2022) Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction. Circulation: Heart Failure, 15(10), pp. 988-990. (doi: 10.1161/CIRCHEARTFAILURE.121.009295) (PMID:35924555)

Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)

Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)

Kobayashi, M. et al. (2022) The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 24(9), pp. 1559-1568. (doi: 10.1002/ejhf.2579) (PMID:35703355)

Vaduganathan, M., Ferreira, J. P., Rossignol, P., Neuen, B., Claggett, B. L., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Zannad, F. and Solomon, S. D. (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. European Journal of Heart Failure, 24(9), pp. 1586-1590. (doi: 10.1002/ejhf.2635) (PMID:35867859)

Verdonschot, J. A.J. et al. (2022) The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial. Journal of Cardiac Failure, 28(5), pp. 778-786. (doi: 10.1016/j.cardfail.2021.12.005) (PMID:34933097)

Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)

Ferreira, J. P., Cleland, J. G. , Lam, C. S.P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., LaPolice, D. A., Greenberg, B. and Zannad, F. (2022) New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, 111(1), pp. 50-59. (doi: 10.1007/s00392-021-01891-2) (PMID:34128083)

2021

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Raafs, A. et al. (2021) Identification of sex‐specific biomarkers predicting new‐onset heart failure. ESC Heart Failure, 8(5), pp. 3512-3520. (doi: 10.1002/ehf2.13476) (PMID:34156155) (PMCID:PMC8497379)

Ferreira, J. P. et al. (2021) Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 117(10), pp. 2228-2236. (doi: 10.1093/cvr/cvaa279) (PMID:33002110)

Verdonschot, J. A.J. et al. (2021) Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 20, 163. (doi: 10.1186/s12933-021-01357-9)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)

Ferreira, J. P., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., La Police, D. A., Cleland, J. G.F. , Greenberg, B. and Zannad, F. (2021) Plasma D‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial. European Journal of Heart Failure, 23(4), pp. 648-656. (doi: 10.1002/ejhf.2003) (PMID:32959502)

Ferreira, J. P. et al. (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC: Heart Failure, 9(4), pp. 268-277. (doi: 10.1016/j.jchf.2020.11.010) (PMID:33549556)

Ferreira, J. P. et al. (2021) Impact of geographic region on the COMMANDER-HF Trial. JACC: Heart Failure, 9(3), pp. 201-211. (doi: 10.1016/j.jchf.2020.11.007) (PMID:33549557)

2020

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

2019

Mehra, M. R. et al. (2019) A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 40(44), pp. 3593-3602. (doi: 10.1093/eurheartj/ehz427) (PMID:31461239) (PMCID:PMC6868495)

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi: 10.1161/CIRCHEARTFAILURE.118.005897) (PMID:31104495)

Rossello, X., Ferreira, J. P., McMurray, J. J.V. , Aguilar, D., Pfeffer, M. A., Pitt, B., Dickstein, K., Girerd, N., Rossignol, P. and Zannad, F. (2019) Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 8(3), pp. 231-241. (doi: 10.1177/2048872618803701) (PMID:30259764)

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)

Articles

Yu, Y.-L. et al. (2024) Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart, 110(19), pp. 1180-1187. (doi: 10.1136/heartjnl-2023-323796) (PMID:38729636)

Aguiar-Neves, I. et al. (2024) Health status and effects of spironolactone in people at high risk of heart failure: the Heart OMics in AGEing (HOMAGE) randomised trial. Clinical Cardiology, (Accepted for Publication)

Kobayashi, M. et al. (2024) Proteomic profiles of left atrial volume and its influence on response to spironolactone: findings from the HOMAGE trial and STANISLAS cohort. European Journal of Heart Failure, 26(5), pp. 1231-1241. (doi: 10.1002/ejhf.3202) (PMID:38528728)

Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, 30(4), pp. 618-623. (doi: 10.1016/j.cardfail.2023.11.020) (PMID:38122924)

Sattar, N. et al. (2024) Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: principal findings and meta-analysis with the DELIVER trial. European Journal of Heart Failure, 26(4), pp. 900-909. (doi: 10.1002/ejhf.3221) (PMID:38558521)

Santos-Ferreira, D. et al. (2024) Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial. ESC Heart Failure, 11(1), pp. 209-218. (doi: 10.1002/ehf2.14465) (PMID:37939716) (PMCID:PMC10804163)

Neves, J. S. et al. (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp. 517-525. (doi: 10.1016/j.jacc.2023.05.048) (PMID:37532422)

Kobayashi, M. et al. (2023) A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial. European Journal of Heart Failure, 25(8), pp. 1284-1289. (doi: 10.1002/ejhf.2859) (PMID:37062878)

Monzo, L., Girerd, N., Duarte, K., Ferreira, J. P., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Pocock, S. J., Pitt, B. and Zannad, F. (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial. European Journal of Heart Failure, 25(8), pp. 1444-1449. (doi: 10.1002/ejhf.2952) (PMID:37370197)

Verma, S. et al. (2023) Presence of peripheral artery disease is associated with increased risk of heart failure events: insights from EMPEROR-Pooled. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(7), pp. 1334-1337. (doi: 10.1161/ATVBAHA.123.319156) (PMID:37199158) (PMCID:PMC10281175)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Girerd, N. et al. (2023) Protein biomarkers of new-onset heart failure: insights from the Heart Omics and Ageing cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circulation: Heart Failure, 16(5), pp. 426-441. (doi: 10.1161/CIRCHEARTFAILURE.122.009694) (PMID:37192292) (PMCID:PMC10179982)

Ferreira, J. P. et al. (2023) Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: pooled analysis of three randomized trials. International Journal of Cardiology, 377, pp. 86-88. (doi: 10.1016/j.ijcard.2023.01.088) (PMID:36738846)

Ferreira, J. P. et al. (2023) Effect of spironolactone on QRS duration in patients at risk for heart failure (from the HOMAGE trial). American Journal of Cardiology, 191, pp. 39-42. (doi: 10.1016/j.amjcard.2022.12.016)

Anker, S. D. et al. (2023) Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. European Journal of Heart Failure, 25(1), pp. 117-127. (doi: 10.1002/ejhf.2728) (PMID:36325584)

Ferreira, J. P. et al. (2023) Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. European Journal of Heart Failure, 25(1), pp. 108-113. (doi: 10.1002/ejhf.2726) (PMID:36303266)

Zannad, F. et al. (2022) Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights from the EMPEROR program. European Heart Journal, 43(48), pp. 4991-5002. (doi: 10.1093/eurheartj/ehac495) (PMID:36017745)

Ferreira, J. P., Pitt, B., McMurray, J. J.V. , Pocock, S. J., Solomon, S. D., Pfeffer, M. A., Zannad, F. and Rossignol, P. (2022) Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs. JACC: Heart Failure, 10(11), pp. 842-850. (doi: 10.1016/j.jchf.2022.06.010) (PMID:36328653)

Bedrouni, W. et al. (2022) Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction. Circulation: Heart Failure, 15(10), pp. 988-990. (doi: 10.1161/CIRCHEARTFAILURE.121.009295) (PMID:35924555)

Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)

Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)

Kobayashi, M. et al. (2022) The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 24(9), pp. 1559-1568. (doi: 10.1002/ejhf.2579) (PMID:35703355)

Vaduganathan, M., Ferreira, J. P., Rossignol, P., Neuen, B., Claggett, B. L., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Zannad, F. and Solomon, S. D. (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. European Journal of Heart Failure, 24(9), pp. 1586-1590. (doi: 10.1002/ejhf.2635) (PMID:35867859)

Verdonschot, J. A.J. et al. (2022) The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial. Journal of Cardiac Failure, 28(5), pp. 778-786. (doi: 10.1016/j.cardfail.2021.12.005) (PMID:34933097)

Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)

Ferreira, J. P., Cleland, J. G. , Lam, C. S.P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., LaPolice, D. A., Greenberg, B. and Zannad, F. (2022) New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, 111(1), pp. 50-59. (doi: 10.1007/s00392-021-01891-2) (PMID:34128083)

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Raafs, A. et al. (2021) Identification of sex‐specific biomarkers predicting new‐onset heart failure. ESC Heart Failure, 8(5), pp. 3512-3520. (doi: 10.1002/ehf2.13476) (PMID:34156155) (PMCID:PMC8497379)

Ferreira, J. P. et al. (2021) Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 117(10), pp. 2228-2236. (doi: 10.1093/cvr/cvaa279) (PMID:33002110)

Verdonschot, J. A.J. et al. (2021) Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 20, 163. (doi: 10.1186/s12933-021-01357-9)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)

Ferreira, J. P., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., La Police, D. A., Cleland, J. G.F. , Greenberg, B. and Zannad, F. (2021) Plasma D‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial. European Journal of Heart Failure, 23(4), pp. 648-656. (doi: 10.1002/ejhf.2003) (PMID:32959502)

Ferreira, J. P. et al. (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC: Heart Failure, 9(4), pp. 268-277. (doi: 10.1016/j.jchf.2020.11.010) (PMID:33549556)

Ferreira, J. P. et al. (2021) Impact of geographic region on the COMMANDER-HF Trial. JACC: Heart Failure, 9(3), pp. 201-211. (doi: 10.1016/j.jchf.2020.11.007) (PMID:33549557)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

Mehra, M. R. et al. (2019) A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 40(44), pp. 3593-3602. (doi: 10.1093/eurheartj/ehz427) (PMID:31461239) (PMCID:PMC6868495)

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi: 10.1161/CIRCHEARTFAILURE.118.005897) (PMID:31104495)

Rossello, X., Ferreira, J. P., McMurray, J. J.V. , Aguilar, D., Pfeffer, M. A., Pitt, B., Dickstein, K., Girerd, N., Rossignol, P. and Zannad, F. (2019) Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 8(3), pp. 231-241. (doi: 10.1177/2048872618803701) (PMID:30259764)

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)